Home › Research › Biomarkers
Clinical validation of a plasma p ‐tau217 immunoassay and evaluation of the impact of kidney function
Heather A. Nelson, Sonia L. La’ulu, J. Alan Erickson, Sierra Cunningham, Kelly J. Doyle. Alzheimer s & Dementia, 2025-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
. The area under the receiver operating characteristic curve of plasma p -tau217 was 0.941. The two cut points established resulted in a sensitivity of 90%, specificity of 90%, negative predictive value of 84%, positive predictive value of 94%, and a percent indeterminate of 17%, with a false positive rate of 2.9% and false negative rate of 5.2% (Table 1). When p -tau217 concentrations were stratified by Aβ+ and eGFR status, there was no significant change in p -tau217 in individuals with reduced eGFR compared to those with normal kidney function in amyloid negative (p -value=0.45, Kruskal-Wallis-test) or amyloid positive (p -value=0.11, Kruskal-Wallis-test) individuals (Table 2). This plasma p -tau217 assay has high concordance with amyloid PET and may aid in the diagnostic workup of AD. Furthermore, quantification of p -tau217 using this assay was not impacted by reduced eGFR status, suggesting it can provide reliable results in individuals with renal impairment.
What this study adds
Evidence grade: Low
This plasma p-tau217 test showed high agreement with amyloid PET, with 90% sensitivity and 90% specificity, and its measurements were not significantly affected by reduced kidney function. Reported effect size: 2.9%; 5.2%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nelson, H. A., La’ulu, S. L., Erickson, J. A., Cunningham, S., & Doyle, K. J. (2025). Clinical validation of a plasma p ‐tau217 immunoassay and evaluation of the impact of kidney function. Alzheimer s & Dementia. https://doi.org/10.1002/alz70861_108683
Vancouver
Nelson HA, La’ulu SL, Erickson JA, Cunningham S, Doyle KJ. Clinical validation of a plasma p ‐tau217 immunoassay and evaluation of the impact of kidney function. Alzheimer s & Dementia. 2025. doi:10.1002/alz70861_108683. PMID: 41433690.
BibTeX
@article{nelson2025-41433690,
author = {Nelson, Heather A. and La’ulu, Sonia L. and Erickson, J. Alan and Cunningham, Sierra and Doyle, Kelly J.},
title = {{Clinical validation of a plasma p ‐tau217 immunoassay and evaluation of the impact of kidney function}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70861_108683},
pmid = {41433690},
url = {https://doi.org/10.1002/alz70861_108683}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The area under the receiver operating characteristic curve of plasma p -tau217 was 0.941.
- The two cut points established resulted in a sensitivity of 90%, specificity of 90%, negative predictive value of 84%, positive predictive value of 94%, and a percent indeterminate of 17%, with a false positive rate of 2.9% and false negative rate of 5.2% (Table 1).
- When p -tau217 concentrations were stratified by Aβ+ and eGFR status, there was no significant change in p -tau217 in individuals with reduced eGFR compared to those with normal kidney function in amyloid negative (p -value=0.45, Kruskal-Wallis-test) or amyloid positive (p -value=0.11, Kruskal-Wallis-test) individuals (Table 2).
- This plasma p -tau217 assay has high concordance with amyloid PET and may aid in the diagnostic workup of AD.
- Furthermore, quantification of p -tau217 using this assay was not impacted by reduced eGFR status, suggesting it can provide reliable results in individuals with renal impairment.
Why it matters
This plasma p-tau217 test showed high agreement with amyloid PET, with 90% sensitivity and 90% specificity, and its measurements were not significantly affected by reduced kidney function. The authors conclude it may aid in the diagnostic workup of Alzheimer's disease and can give reliable results in people with kidney impairment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect size2.9%; 5.2%
- Evidence strengthLow
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Kelly J. Doyle: h-index 12 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Utah: institution h-index 1,238 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41433690) |
| Free to read | 2 / 2 | Free to read |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70861_108683
- PubMed: 41433690
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.